Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.11
At close: Mar 15, 5:00 PM EST
$0.00020
-1.11-99.98%
After Hours: Mar 16, 4:56 PM EST
Panbela Therapeutics Inc Analyst Ratings
PBLAOTCEM
Panbela Therapeutics Analyst Ratings and Price Targets | OTC:PBLA | Benzinga
Panbela Therapeutics Inc has a consensus price target of $25 based on the ratings of 2 analysts. The high is $25 issued by Roth MKM on March 27, 2024. The low is $25 issued by Roth MKM on March 27, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Roth MKM, and Roth MKM on April 2, 2024, March 27, 2024, and February 5, 2024, respectively. With an average price target of $18.33 between HC Wainwright & Co., Roth MKM, and Roth MKM, there's an implied 1833233.33% upside for Panbela Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Roth MKM
1calculated from analyst ratings
Analyst Ratings for Panbela Therapeutics
Loading calendar...
FAQ
What is the target price for Panbela Therapeutics (PBLA) stock?
The latest price target for Panbela Therapeutics (OTCEM:PBLA) was reported by HC Wainwright & Co. on August 15, 2024. The analyst firm set a price target for $0.00 expecting PBLA to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Panbela Therapeutics (PBLA)?
The latest analyst rating for Panbela Therapeutics (OTCEM:PBLA) was provided by HC Wainwright & Co., and Panbela Therapeutics reiterated their neutral rating.
When was the last upgrade for Panbela Therapeutics (PBLA)?
There is no last upgrade for Panbela Therapeutics
When was the last downgrade for Panbela Therapeutics (PBLA)?
The last downgrade for Panbela Therapeutics Inc happened on May 16, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Panbela Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Panbela Therapeutics (PBLA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Panbela Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Panbela Therapeutics was filed on August 15, 2024 so you should expect the next rating to be made available sometime around August 15, 2025.
Is the Analyst Rating Panbela Therapeutics (PBLA) correct?
While ratings are subjective and will change, the latest Panbela Therapeutics (PBLA) rating was a reiterated with a price target of $0.00 to $0.00. The current price Panbela Therapeutics (PBLA) is trading at is $0.00, which is out of the analyst’s predicted range.
